Silly question: now that we have ph1 complete for MND. Assuming no alteration to formulation of MPL or dosage, could we jump straight to Ph2 for other conditions?
Or do we still need to determine safety specifically for people with a particular condition? Would it depend on the condition per regulatory board adjudication?
- Forums
- ASX - By Stock
- PAA
- The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1077
-
- There are more pages in this discussion • 348 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
23.5¢ |
Change
-0.005(2.08%) |
Mkt cap ! $93.03M |
Open | High | Low | Value | Volume |
24.0¢ | 26.0¢ | 23.0¢ | $579.7K | 2.369M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 29999 | 23.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.0¢ | 79713 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 29999 | 0.235 |
2 | 193065 | 0.230 |
5 | 105388 | 0.225 |
7 | 223408 | 0.220 |
5 | 55744 | 0.215 |
Price($) | Vol. | No. |
---|---|---|
0.240 | 79713 | 4 |
0.250 | 23920 | 5 |
0.255 | 1062460 | 3 |
0.260 | 311980 | 3 |
0.265 | 181000 | 2 |
Last trade - 16.10pm 12/06/2024 (20 minute delay) ? |
|
|||||
Last
23.5¢ |
  |
Change
-0.005 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
24.0¢ | 25.8¢ | 23.5¢ | 1174846 | ||
Last updated 15.54pm 12/06/2024 ? |
Featured News
PAA (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
SPONSORED BY The Market Online